<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04393779</url>
  </required_header>
  <id_info>
    <org_study_id>2019-12</org_study_id>
    <nct_id>NCT04393779</nct_id>
  </id_info>
  <brief_title>Observational Registry on the HARPOON Device</brief_title>
  <acronym>REPLICATE</acronym>
  <official_title>Beating Heart Mitral Valve REPair With the HARPOON™ System: ReaL World Outcomes From a multICenter observATional European Registry</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Edwards Lifesciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>MedPass International</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Edwards Lifesciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      To collect data on the HARPOON™ Mitral Valve Repair System for use in patients with severe
      degenerative mitral regurgitation due to posterior leaflet prolapse.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a single arm, prospective, multicenter, post-market, observational registry that will
      evaluate subjects for up to 5 years post treatment.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 2020</start_date>
  <completion_date type="Anticipated">June 2027</completion_date>
  <primary_completion_date type="Anticipated">January 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Single arm study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Freedom from re-operation due to recurrent severe mitral regurgitation through 1-year post-implant</measure>
    <time_frame>1 year post-implant</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Severe Degenerative Mitral Regurgitation Due to Mid-segment Posterior Leaflet Prolapse</condition>
  <arm_group>
    <arm_group_label>HARPOON™ MVRS</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Subjects who were treated with the HARPOON MVRS.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>HARPOON Beating Heart Mitral Valve Repair System (MVRS)</intervention_name>
    <description>Repair of the chordae tendinae in the mitral valve.</description>
    <arm_group_label>HARPOON™ MVRS</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects who are clinically suitable for treatment with the HARPOON™ System, as per
             the Instructions for Use (IFU), will be evaluated for inclusion in the registry.

        Exclusion Criteria:

          -  N/A
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Prof. Dr. Thomas Walther</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Frankfurt</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sabrina Hundt</last_name>
    <phone>949-250-2500</phone>
    <email>sabrina_hundt@edwards.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Marieke Vijge</last_name>
    <phone>949-250-2500</phone>
    <email>Mareke_Vijge@edwards.com</email>
  </overall_contact_backup>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>May 14, 2020</study_first_submitted>
  <study_first_submitted_qc>May 14, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 19, 2020</study_first_posted>
  <last_update_submitted>May 14, 2020</last_update_submitted>
  <last_update_submitted_qc>May 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Mitral valve</keyword>
  <keyword>Mid-segment posterior leaflet prolapse of the mitral valve</keyword>
  <keyword>Heart valve</keyword>
  <keyword>Chordae tendinae</keyword>
  <keyword>Valve disease</keyword>
  <keyword>Mitral Regurgitation</keyword>
  <keyword>Harpoon</keyword>
  <keyword>Mitral valve repair</keyword>
  <keyword>Posterior leaflet prolapse</keyword>
  <keyword>Beating heart intervention</keyword>
  <keyword>Heart disease</keyword>
  <keyword>Cardiovascular disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mitral Valve Insufficiency</mesh_term>
    <mesh_term>Prolapse</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

